

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

November 1st, 2023

Abstract of the summary presentation of the US Phase 1/2 clinical trial of CTX-712 has been accepted at the 65th American Society of Hematology Annual meeting.

Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the research and development of novel therapies for cancers, today pleased to announce that an abstract has been accepted for an overview of our Phase 1/2 clinical trial of CTX-712 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes(MDS) at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, USA, from 9-12 December 2023, where the following poster presentation will be given.

Abstract No	3249
Title	Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Session No	637
Time	6 pm – 8 pm December 10 2023

About AML and MDS

AML and MDS are diseases in which abnormal stem cells (abnormal clones) grow tumorigenic ally in the bone marrow and suppress normal hematopoiesis. Both diseases have not definitely effective second-line therapies, have poor prognoses, and have a high unmet medical need.

About CTX-712

CTX-712 is a first-in-class, orally available and selective small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays an important role in cell growth. CTX-712 inhibits the growth of various human tumor cell lines *in vitro*, and in addition, exhibits antitumor activity in multiple xenograft mouse models *in vivo*. For more information about The US Phase 1/2 clinical trial of CTX-712, please visit the following website: clinicaltrials.gov/ (NCT05732103).

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers. Chordia’s lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan and Phase1/2 clinical study in US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets,

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

info@chorditherapeutics.com



including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: ir@chorditherapeutics.com